These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 27939012)

  • 1. Immunofocusing using conformationally constrained V3 peptide immunogens improves HIV-1 neutralization.
    Moseri A; Sinha E; Zommer H; Arshava B; Naider F; Anglister J
    Vaccine; 2017 Jan; 35(2):222-230. PubMed ID: 27939012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.
    Kumar R; Pan R; Upadhyay C; Mayr L; Cohen S; Wang XH; Balasubramanian P; Nádas A; Seaman MS; Zolla-Pazner S; Gorny MK; Kong XP; Hioe CE
    J Virol; 2015 Sep; 89(17):9090-102. PubMed ID: 26109728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergism between a CD4-mimic peptide and antibodies elicited by a constrained V3 peptide.
    Moseri A; Tantry S; Ding FX; Naider F; Anglister J
    AIDS Res Hum Retroviruses; 2013 Apr; 29(4):718-24. PubMed ID: 23176398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.
    Andrabi R; Kumar R; Bala M; Nair A; Biswas A; Wig N; Kumar P; Pal R; Sinha S; Luthra K
    Virol J; 2012 Sep; 9():196. PubMed ID: 22971578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk.
    Martinez DR; Vandergrift N; Douglas AO; McGuire E; Bainbridge J; Nicely NI; Montefiori DC; Tomaras GD; Fouda GG; Permar SR
    J Virol; 2017 May; 91(9):. PubMed ID: 28202762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes.
    Cardozo T; Wang S; Jiang X; Kong XP; Hioe C; Krachmarov C
    Vaccine; 2014 Sep; 32(39):4916-24. PubMed ID: 25045827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120.
    Moseri A; Tantry S; Sagi Y; Arshava B; Naider F; Anglister J
    Virology; 2010 Jun; 401(2):293-304. PubMed ID: 20347111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
    Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
    J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits.
    Rangasamy SP; Menon V; Dhopeshwarkar P; Pal R; Vaniambadi KS; Mahalingam S
    Vaccine; 2016 May; 34(21):2444-2452. PubMed ID: 27032514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
    Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
    J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens.
    Conley AJ; Conard P; Bondy S; Dolan CA; Hannah J; Leanza WJ; Marburg S; Rivetna M; Rusiecki VK; Sugg EE
    Vaccine; 1994 Apr; 12(5):445-51. PubMed ID: 8023553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.
    Young KR; Teal BE; Brooks Y; Green TD; Bower JF; Ross TM
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1259-68. PubMed ID: 15588348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.
    Zolla-Pazner S; Kong XP; Jiang X; Cardozo T; Nádas A; Cohen S; Totrov M; Seaman MS; Wang S; Lu S
    J Virol; 2011 Oct; 85(19):9887-98. PubMed ID: 21795338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.
    Zolla-Pazner S; Cohen SS; Boyd D; Kong XP; Seaman M; Nussenzweig M; Klein F; Overbaugh J; Totrov M
    J Virol; 2016 Jan; 90(2):636-49. PubMed ID: 26491157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization.
    White-Scharf ME; Potts BJ; Smith LM; Sokolowski KA; Rusche JR; Silver S
    Virology; 1993 Jan; 192(1):197-206. PubMed ID: 7685962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
    Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
    J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.
    Charles-Niño C; Pedroza-Roldan C; Viveros M; Gevorkian G; Manoutcharian K
    Vaccine; 2011 Jul; 29(32):5313-21. PubMed ID: 21600948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.